Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer

Eleni Efstathiou • 30 May 2015
ASCO 2015
Genitourinary Cancer Prostate Cancer Abiraterone Leuprolide

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer.

More from Eleni Efstathiou

1:18
Making advances in prostate cancer
Eleni Efstathiou • 1 Jun 2017
2:31
Abiraterone: a step forward in the treatment of prostate cancer
Eleni Efstathiou • 1 Jun 2017
1:32
Biomarkers for the management of prostate cancer
Eleni Efstathiou • 30 May 2015
2:45
Trial of LHRHa, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
Eleni Efstathiou • 3 Jun 2016

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals